Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and NeckRobert L. Ferris, Maura L. Gillison, Lara Carmen Iglesias Docampo et al.|New England Journal of Medicine|2016Cited by 5.1k
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trialKevin J. Harrington, J. Guigay, Robert L. Ferris et al.|The Lancet Oncology|2017Cited by 431
CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck CancerMaura L. Gillison, Robert L. Ferris, George R. Blumenschein et al.|The Oncologist|2018Cited by 96
Further evaluations of nivolumab (nivo) versus investigator’s choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141.Robert L. Ferris, Maura L. Gillison, George R. Blumenschein et al.|Journal of Clinical Oncology|2016Cited by 53
Abstract CT099: Nivolumab (nivo) vs investigator's choice (IC) for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): CheckMate-141Maura L. Gillison, Robert L. Ferris, George R. Blumenschein et al.|Cancer Research|2016Cited by 36